NPHLA Intelligence
Clinical Trial Watch
Trials NPHLA follows, synchronised from ClinicalTrials.gov. We flag what matters (new registrations, changes in status and newly posted results) and ignore routine record edits. Every therapy in a trial is investigational.
- SURMOUNT-1: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Hudson Biotech. Conditions: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. Investigational — not approved for the use studied.
- A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control
Lembas. Conditions: Postprandial Glycemic Control; Prediabetic Overweight and Obese Adults. Investigational — not approved for the use studied.
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Vanderbilt University Medical Center. Conditions: Duchenne Muscular Dystrophy (DMD). Investigational — not approved for the use studied.
- PORTIONS_V_RCT: Comprehensive Intervention for Changing Eating Habits Through Portion Control
Clinica Universidad de Navarra, Universidad de Navarra. Conditions: Lifestyle Intervention; Weight Management; Behaviour Change; Portion Size. Investigational — not approved for the use studied.
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
Shanghai Zhongshan Hospital. Conditions: Obesity; Weight Control. Investigational — not approved for the use studied.
- A Study to Evaluate ALN-2232 in Participants With Obesity
Alnylam Pharmaceuticals. Conditions: Obesity. Investigational — not approved for the use studied.
- TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu. Conditions: Acute Ischemic Stroke (AIS). Status changed from “Not yet recruiting” on Nov 12, 2026. Investigational — not approved for the use studied.
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
Hoffmann-La Roche. Conditions: Type 2 Diabetes Mellitus. Status changed from “Active, not recruiting” on Nov 12, 2026. Investigational — not approved for the use studied.
- GZBF: Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
Hudson Biotech. Conditions: Obesity. Investigational — not approved for the use studied.
- Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
National Institute on Alcohol Abuse and Alcoholism (NIAAA). Conditions: Healthy Volunteers; Overweight. Investigational — not approved for the use studied.
- The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes
Imperial College London. Conditions: Steroid-Induced Diabetes; Steroid Induced Hyperglycemia. Investigational — not approved for the use studied.
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Regeneron Pharmaceuticals. Conditions: Hidradenitis Suppurativa. Investigational — not approved for the use studied.
- IMPACT: The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity
Radboud University Medical Center. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction
Benjamin T. Miller. Conditions: Abdominal Wall Hernia. Investigational — not approved for the use studied.
- PRE-CARE-DIET: Precision Nutrition to Improve Cardiometabolic Health With Dietary (Poly)Phenols
University of Parma. Conditions: Individual Variability in (Poly)Phenol Metabolism; Cardiometabolic Health; Personalized Dietary Intervention; Obesity. Investigational — not approved for the use studied.
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
Institute of Liver and Biliary Sciences, India. Conditions: Chronic Kidney Diseases; MAFLD. Investigational — not approved for the use studied.
- GLP1: Semaglutide in Youth With Autism Spectrum Disorder
Children's Hospital Medical Center, Cincinnati. Conditions: Autism Spectrum Disorder; Obesity. Investigational — not approved for the use studied.
- Ocular Changes in Patients Using Tirzepatide or Semaglutide
Istanbul University. Conditions: Type 2 Diabetes Mellitus; Obesity. Investigational — not approved for the use studied.
- Enith1: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche. Conditions: Obesity or Overweight. Investigational — not approved for the use studied.
- Enith2: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche. Conditions: Obesity or Overweight; Type 2 Diabetes Mellitus. Investigational — not approved for the use studied.
- Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
AstraZeneca. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
The Methodist Hospital Research Institute. Conditions: Alzheimer Dementia (AD). Investigational — not approved for the use studied.
- GLP-BARI-VAN: Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
Yuzuncu Yil University. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen. Conditions: Obesity or Overweight. Investigational — not approved for the use studied.
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals. Conditions: Overweight or Obesity. Investigational — not approved for the use studied.
- A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Pfizer. Conditions: Obesity; Overweight; Osteoarthritis of the Knee. Investigational — not approved for the use studied.
- Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Medical College of Wisconsin. Conditions: Psoriatic Arthritis (PsA). Investigational — not approved for the use studied.
- Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
University of Texas Southwestern Medical Center. Conditions: Heart Failure; Diabetes. Investigational — not approved for the use studied.
- MARITIME-T2D-3: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Amgen. Conditions: Diabetes Mellitus, Type 2. Status changed from “Not yet recruiting” on Nov 5, 2026. Investigational — not approved for the use studied.
- A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Hoffmann-La Roche. Conditions: Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM). Investigational — not approved for the use studied.
- ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company. Conditions: Diabetes Mellitus, Type 2. Status changed from “Not yet recruiting” on Oct 19, 2026. Investigational — not approved for the use studied.
- ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company. Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Investigational — not approved for the use studied.
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Pfizer. Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Status changed from “Not yet recruiting” on Oct 15, 2026. Investigational — not approved for the use studied.
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Eli Lilly and Company. Conditions: Psoriasis; Overweight or Obesity. Investigational — not approved for the use studied.
- Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication
University of California, Los Angeles. Conditions: Obesity & Overweight; Muscle Mass and Strength; Muscle Function. Investigational — not approved for the use studied.
- A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Pfizer. Conditions: Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2. Investigational — not approved for the use studied.
- AI-LIFE-T2D-OB: AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
The First Affiliated Hospital of Anhui Medical University. Conditions: Obesity; Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- SEMA AUD: Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Yale University. Conditions: Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30). Investigational — not approved for the use studied.
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
University of Colorado, Denver. Conditions: Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular. Investigational — not approved for the use studied.
- AMPLIFY-2: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company. Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Status changed from “Not yet recruiting” on Nov 4, 2026. Investigational — not approved for the use studied.
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- COMMIT-CD: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company. Conditions: Crohn's Disease; Obesity or Overweight. Investigational — not approved for the use studied.
- COMMIT-UC: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company. Conditions: Ulcerative Colitis; Obesity or Overweight. Investigational — not approved for the use studied.
- Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Eli Lilly and Company. Conditions: Obesity. Status changed from “Not yet recruiting” on Oct 13, 2026. Investigational — not approved for the use studied.
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company. Conditions: Urinary Incontinence,Stress. Investigational — not approved for the use studied.
- ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Eli Lilly and Company. Conditions: Peripheral Arterial Disease. Investigational — not approved for the use studied.
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Eli Lilly and Company. Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Investigational — not approved for the use studied.
- ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
- Tirzepatide for Treatment of CCCA
Johns Hopkins University. Conditions: Central Centrifugal Cicatricial Alopecia (CCCA). Investigational — not approved for the use studied.
- An Open Label Pilot Study Assessing the Impact of Chromium Picolinate Supplementation on Appetite and Cravings in Overweight Individuals
Nutrition 21, Inc.. Conditions: Overweight (BMI > 25); Appetite; Craving. Investigational — not approved for the use studied.
- Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Amgen. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Shanghai JMT-Bio Inc.. Conditions: Valid MeSH Conditiongs. Investigational — not approved for the use studied.
- Hypothalamic GLP-1 Response in Healthy Weight and Obesity
University of Copenhagen. Conditions: Obesity; Normal Weight; Glucose Intolerance. Status changed from “Not yet recruiting” on Nov 2, 2026. Investigational — not approved for the use studied.
- TCPT2023: Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer
Azienda Ospedaliero Universitaria Maggiore della Carita. Conditions: Diabetes Mellitus, Type 2; Cancer. Investigational — not approved for the use studied.
- FutureShape Family
Signe Torekov. Conditions: Obesity; Overweight. Status changed from “Not yet recruiting” on Oct 29, 2026. Investigational — not approved for the use studied.
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Novo Nordisk A/S. Conditions: Cardiovascular Risk; Chronic Kidney Disease. Investigational — not approved for the use studied.
- JOULE3: Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
McMaster University. Conditions: Obesity (Disorder). Investigational — not approved for the use studied.
- Healthy Living BEYOND Weight Study
American Heart Association. Conditions: Overweight or Obesity. Investigational — not approved for the use studied.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Trial listings are not recommendations to enrol or prescribe.